Changes to the Roche Corporate Executive Committee
Basel, 28 August 2012
Daniel O’Day appointed new Head of Roche Pharma– Roland Diggelmann will assume the position Head of Roche Diagnostics
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Daniel O’Day, currently Chief Operating Officer (COO) of Roche Diagnostics has been appointed as COO of Roche Pharma effective September 1, 2012. He will succeed Pascal Soriot, who will leave Roche and take on new responsibilities outside the Group. Daniel O’Day will be succeeded by Roland Diggelmann, currently Head of the Asia-Pacific Region within Roche Diagnostics, who has been appointed as a new member of the Executive Committee by the Board of Directors.
Severin Schwan, CEO of Roche, said: “Pascal Soriot has made a significant contribution to the successful integration of Genentech and has successfully led the Pharmaceuticals division in an increasingly challenging market environment. I am very pleased that with Daniel O’Day we are appointing a new Head of Roche Pharma with a very impressive track record in both the Diagnostics and Pharmaceuticals division. Roland Diggelmann, the new Head of Roche Diagnostics, has a broad and internationally based commercial and marketing experience.”
Daniel O’Day, a U.S. citizen, was born in 1964. He began his career in 1987 at Roche in the U.S. Pharmaceuticals organization in Sales and Marketing. Afterwards, he held various positions in Roche Pharma in Switzerland, Japan, and Denmark. In 2006 O’Day joined Roche Diagnostics and became Head of the Business Area Molecular Diagnostics. On January 1 2010 he was appointed Chief Operating Officer for Roche’s global diagnostics business.
Roland Diggelmann, a Swiss citizen, was born in 1967. Before joining Roche in 2008, he held various leading positions in Sales and Marketing in Europe and Asia-Pacific with the medical technology companies Sulzer Medica/Centerpulse and Zimmer. He was also responsible for the integration of Centerpulse’s Japanese business into Zimmer. At Roche Diagnostics, he has led the region Asia-Pacific since 2008 as member of the divisional leadership team.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.